Companies: 49,246 Total Market Cap: 132387819536209.04

Neuren Pharmaceuticals Limited

ASX-NEU
Healthcare Biotechnology
Rank #9152
Market Cap 1.03 B
Volume 148,717
Price 8.27
Change (%) 1.98%
Country or region New Zealand New Zealand

Neuren Pharmaceuticals Limited's latest marketcap:

1.03 B

As of 05/20/2025, Neuren Pharmaceuticals Limited's market capitalization has reached $1.03 B. According to our data, Neuren Pharmaceuticals Limited is the 9152th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 1.03 B
Revenue (ttm) 139.21 M
Net Income (ttm) 91.19 M
Shares Out 124.70 M
EPS (ttm) 0.70
Forward PE 97.33
Ex-Dividend Date n/a
Earnings Date 05/30/2025
Market Cap Chart
Data Updated: 05/20/2025

Neuren Pharmaceuticals Limited's yearly market capitalization.

Neuren Pharmaceuticals Limited has seen its market value grow from A$147.27 M to A$1.60 B since 2020, representing a total increase of 985.47% and an annual compound growth rate (CAGR) of 72.24%.
Date Market Cap Change (%)
05/20/2025 A$1.60 B -2.78%
12/31/2024 A$1.59 B -50.04%
12/29/2023 A$3.18 B 217.33%
12/30/2022 A$1.00 B 110.88%
12/31/2021 A$474.89 M 222.46%
12/31/2020 A$147.27 M

Company Profile

Neuren Pharmaceuticals Limited

Company Overview: Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of drugs for neurological disorders. Founded in 2001 and headquartered in Camberwell, Australia, the company focuses on innovative treatments for rare and complex neurological conditions.

Key Developments & Pipeline

  • DAYBUE (trofinetide): Approved for the treatment of Rett syndrome in adults and pediatric patients aged 2 years and older. Currently in Phase 2 clinical trials for Fragile X syndrome.
  • NNZ-2591:
    • Completed Phase 2 trials for Phelan-McDermid syndrome.
    • In Phase 2 trials for Angelman syndrome and Pitt Hopkins syndrome.
    • In preclinical development for Prader-Willi syndrome.
Frequently Asked Questions

As of 05/20/2025, Neuren Pharmaceuticals Limited (including the parent company, if applicable) has an estimated market capitalization of $1.03 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Neuren Pharmaceuticals Limited global market capitalization ranking is approximately 9152 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region New Zealand
Founded 2001
IPO Date n/a
Employees 8
CEO Jonathan Pilcher
Sector Healthcare
Industry Biotechnology
Address 697 Burke Road
Camberwell, VIC 3124
Australia
Website https://www.neurenpharma.com
People Also Watch
VRTX
445.19 1.98%
CSL Limited
156.67 1.98%
REGN
610.63 1.98%
KRX-207940
731.22 1.98%